Efficacy of Lactobacillus reuteri DSM 17938 in preterm newborns and infants with colic: a systematic review and meta-analysis of randomized controlled trials.
Marco Bianchi, Giovanna Quatrale, Luigi Colecchia et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of Lactobacillus reuteri DSM 17938 in preterm newborns and infants with colic. The analysis included 11 trials for colicky infants (n = 555) and 8 for preterm infants (n = 1704). The study found that L. reuteri significantly improved treatment response in colicky infants (OR 6.98) and reduced feeding intolerance (OR 0.57) and necrotizing enterocolitis (OR 0.49) in preterm infants.
Key findings
- L. reuteri DSM-17938 increased treatment response in colicky infants (OR 6.98; 95% CI 2.26-21.59).
- Daily crying time in colicky infants was significantly reduced (SD -2.61; 95% CI -3.98 to -1.24).
- Probiotic supplementation reduced feeding intolerance in preterm infants (OR 0.57; 95% CI 0.42-0.79).
- The incidence of necrotizing enterocolitis was significantly reduced (OR 0.49; 95% CI 0.31-0.77).
Why it matters
The findings suggest that Lactobacillus reuteri DSM 17938 may provide significant benefits in managing infantile colic and improving gastrointestinal outcomes in preterm infants, which could enhance clinical care strategies in these vulnerable populations.